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Abstract
Epilepsy is a common and serious neurological disorder, with many different constitu-
ent conditions characterized by their electro clinical, imaging, and genetic features.
MRI has been fundamental in advancing our understanding of brain processes in the
epilepsies. Smaller-scale studies have identified many interesting imaging phenomena,
with implications both for understanding pathophysiology and improving clinical care.
Through the infrastructure and concepts now well-established by the ENIGMA Con-
sortium, ENIGMA-Epilepsy was established to strengthen epilepsy neuroscience by
greatly increasing sample sizes, leveraging ideas and methods established in other
ENIGMA projects, and generating a body of collaborating scientists and clinicians to
drive forward robust research. Here we review published, current, and future pro-
jects, that include structural MRI, diffusion tensor imaging (DTI), and resting state
functional MRI (rsfMRI), and that employ advanced methods including structural
covariance, and event-based modeling analysis. We explore age of onset- and
duration-related features, as well as phenomena-specific work focusing on particular
epilepsy syndromes or phenotypes, multimodal analyses focused on understanding
the biology of disease progression, and deep learning approaches. We encourage
groups who may be interested in participating to make contact to further grow and
develop ENIGMA-Epilepsy.
K E YWORD S
covariance, deep learning, DTI, event-based modeling, gene expression, genetics, imaging, MRI,
quantitative, rsfMRI
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1 | INTRODUCTION
ENIGMA-Epilepsy, the epilepsy working group of ENIGMA, was offi-
cially launched at The Royal Society, London in March 2015 by Chris-
topher Whelan (USC) and Sanjay Sisodiya (UCL) at a meeting of the
International League Against Epilepsy Consortium on Complex Epilep-
sies (https://www.ilae.org/guidelines/complex-epilepsies). The project
has continued to grow since its inception. It is now jointly led by
Carrie McDonald, Christopher Whelan, and Sanjay Sisodiya, and com-
prises 26 collaborating international centers. The original aims of the
group are multiple and include: to create a worldwide network of epi-
lepsy neuroimaging centers; to collect summary statistics on brain
shape, brain volume and white matter connectivity from thousands of
people with epilepsy and thousands of neurologically healthy controls;
to compare and contrast these measures in affected/unaffected
groups and, accordingly, illustrate possible differences between the
two; to identify structural differences between the major forms of
epilepsy and major types of seizure; and to develop collaborations and
infrastructure for future analyses. ENIGMA-Epilepsy was formed with
the intention of applying the idea that had proven effective in other
ENIGMA projects, based on large-scale, world-wide collaborative
efforts merging different types of biological data set (e.g., MRI,
genetic, EEG) to deepen understanding of neurobiology in health and
disease. Building on prior models in neuropsychiatric diseases, such as
schizophrenia (SCZ) and major depressive disorder (MDD), and in
imaging-genetic studies in healthy subjects, ENIGMA-Epilepsy
adopted the template from these existing projects within the ENIGMA
umbrella. We adapted the existing memorandum of understanding
(MoU), and replicated pathways for development and consolidation of
the consortium.
Prior to ENIGMA-Epilepsy, there was a rich existing literature on
MRI in epilepsy, with a number of productive groups working around
the world. MRI had already proven hugely valuable in clinical and
research application in the epilepsies. However, most published stud-
ies were only based on modestly sized samples, with typically fewer
than 100, and often fewer than 50, participants included. Unsurpris-
ingly, the limited power from such studies meant that findings from
different studies of the same problem were often contradictory or
inconclusive. In addition, new methods, many developed or
championed by ENIGMA, were successfully promoting the formal
joint analysis of disparate data sets, whether of the same type spread
across different centers (e.g., in Australia vs. Canada), or of different
types (e.g., MRI vs. genome-wide SNP data). In this context, the for-
mation of ENIGMA-Epilepsy was a natural step forward.
Here we describe projects completed or still in progress within
ENIGMA-Epilepsy, and our hopes for its future. The structure and
workflow is illustrated in Figure 1. We provide contact details and
invite any group with relevant resources and appropriate intent inter-
ested in joining the consortium to get in contact.
2 | PROJECTS AND PUBLICATIONS
The first projects within ENIGMA-Epilepsy were analyses of structural
and diffusion MRI data without any genetic, cognitive, or clinical out-
come data. These projects allowed the consortium to organize itself
and establish a modus operandi, and were based on distributed ana-
lyses, with each center applying a shared processing protocol locally
to its own data (from people with epilepsy and healthy controls
scanned on the same platform), with no exchange of raw image
(i.e., DICOM) data, and subsequent central collation and meta-analysis
and mega-analysis of the processed (i.e., region-of-interest) outputs.
These methods have been of proven utility, and have overcome
platform-related issues in cross-center analysis, as demonstrated by
the extensive publication record of ENIGMA as a whole (Thompson
et al., 2020).
The simplicity and effectiveness of this strategy shaped ENIGMA-
Epilepsy into an operational grouping, and has already led to measur-
able outcomes. The first three projects were a worldwide study of
brain structure in epilepsy, a similar study of diffusion MRI data, and
the first consortium approach to perform joint analysis of multiple
types of data to explore mechanisms underlying findings emerging
from the initial studies that were based solely on imaging data. Build-
ing on these three studies, members were encouraged to propose
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secondary projects, bringing new ideas, methods, and resources to
bear on the collated imaging data set.
2.1 | The first ENIGMA-Epilepsy study: A
worldwide study of brain structural changes in
epilepsy using quantitative structural MRI
By late summer of 2015, the working group had organized its first
conference calls and agreed upon a broad study design, which was to
apply ENIGMA's standardized image processing and meta-analysis
protocols across a large network of research groups, with the broad
goal of identifying robust patterns of gray matter alterations across
different forms of commonly-occurring epilepsy, addressing prior
inconsistencies from smaller-scale studies in the field.
For this inaugural project, the working group set out to compare
data from neurologically healthy individuals (total n = 1,727) to four
broad epilepsy subtypes, including (a) temporal lobe epilepsies (TLE)
with left mesial temporal sclerosis (n = 415), (b) TLE with right mesial
temporal sclerosis (n = 339), (c) genetic generalized epilepsies (GGE;
n = 367), and (d) all other epilepsies (n = 1,026), in addition to a fifth
collection of all epilepsies in aggregate (n = 2,149). Other epilepsy syn-
dromes, such as frontal lobe or occipital lobe epilepsies, were not
considered due to their limited presence across the majority of
research centers. In total, the study included 24 case–control samples,
recruited across 14 countries, aged 18–55 years. All syndromic epi-
lepsy classifications were conducted by clinical epilepsy specialists,
using International League Against Epilepsy (ILAE) systems, with
prespecified inclusion and exclusion criteria (details in Whelan
et al., 2018, Tables S1 and S2). These classifications were carried
through to subsequent studies.
T1-weighted MRI scans were acquired using a variety of plat-
forms at each research center (the majority comprising three Tesla
Siemens or Philips platforms, applying magnetization-prepared rapid
gradient echo [MP-RAGE] sequencing; details provided in Whelan
et al., 2018, Table S3). At each of the 24 sites, a trained neuroimaging
analyst conducted quality assessment of MRI scans using the
ENIGMA protocols, which included an initial segmentation step con-
ducted using FreeSurfer v5.3, whereby 12 subcortical brain regions
and 64 cortical regions were extracted from the T1-weighted image,
followed by a combination of automated outlier detection and
detailed visual inspection for each segmentation. MRI scans from each
of the five predefined epilepsy groups were then compared with
healthy controls using a series of linear regressions in R, adjusting for
age, sex, and intracranial volume. A series of linear regressions testing
the association between brain measures and age at onset of epilepsy,
F IGURE 1 Organizational diagram of ENIGMA-Epilepsy. The flowchart on the left shows the group set up, illustrating source of data used in
subsequent studies. The current workflow is illustrated on the right. ILAE, International League Against Epilepsy; MOU, Memorandum of
Understanding
SISODIYA ET AL. 5
as well as overall duration of epilepsy, was also conducted at each
center. Summary statistics from these analyses (including Cohen's D
effect sizes and regression beta coefficients) were transferred from
each research center to a central analysis laboratory in the Imaging
Genetics Center at the University of Southern California, where they
were pooled across sites using a random-effects meta-analysis model.
F IGURE 2 An illustration of results from the first ENIGMA-Epilepsy study, of brain structural changes in epilepsy using quantitative structural
MRI. Cohen's d effect size estimates for case–control differences in cortical thickness, across the (a) all-epilepsies, (b) mesial temporal lobe
epilepsies with left hippocampal sclerosis (c) mesial temporal lobe epilepsies with right hippocampal sclerosis, (d) idiopathic generalized epilepsies,
and (e) all-other-epilepsies groups. Cohen's d effect sizes were extracted using multiple linear regressions, and pooled across research centers
using random-effects meta-analysis. Cortical structures with p-values <1.49 × 10−4 are shown in heatmap colors; strength of heat map is
determined by the size of the Cohen's d (d < 0 = blue, d > 0 = yellow/red). HS, hippocampal sclerosis. From Whelan et al., 2018
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Given the number of comparisons conducted as part of the study
(336 in total), the typical statistical significance threshold of p < .05
was Bonferroni-adjusted to p < 1.49 × 10−4.
The study revealed a series of robust structural brain alterations,
both within and across epilepsy syndromes (Figure 2) in section 1. As
expected, MTLEs showed profound volume reductions in the hippo-
campus ipsilateral to seizure onset (d < −1.7; p < 1.4 × 10−19). When
compared with healthy controls, left temporal lobe epilepsy (TLE)
appeared to show a more widespread and bilateral distribution of
extrahippocampal gray matter differences than did right TLE, resolving
prior inconsistent findings in smaller-scale studies. The right thalamus
(Cohen's d = −0.24 to −0.73; p < 1.49 × 10−4), and the bilateral
precentral gyri (d = −0.34 to −0.52; p < 4.31 × 10−6) showed evi-
dence of gray matter alterations across all five epilepsy subgroups
when compared with healthy controls, highlighting prior observations
that the thalamus may serve as a “hub” within a distributed function
network that becomes disrupted during epileptogenesis, and re-
emphasizing how focal seizures can lead to persistent, potentially
damaging hyperexcitability in distant cortical regions, particularly the
ipsilateral motor cortices (Hamer et al., 2005). Duration of epilepsy
showed a strong correlation with multiple subcortical volume and cor-
tical thickness measures, in keeping with recent findings that epilepsy
may be associated with progressive cortical atrophy (Galovic
et al., 2019); however, given that, our large study had a cross-sectional
design, these findings strongly emphasize the need for more large-
scale, longitudinal neuroimaging investigations of seizure disorders.
Bilateral enlargement of the amygdala, a finding previously—albeit
inconsistently—reported across “nonlesional” forms of TLE, was seen
in the “all other epilepsies” subgroup, warranting further investigation
of TLE with amygdala enlargement as its own distinct syndrome,
potentially with an autoimmune cause (Malter et al., 2016).
These findings from ENIGMA-Epilepsy's first major study were
discussed during an invited platform presentation at the annual meet-
ing of the Organization for Human Brain Mapping in 2016, and subse-
quently published in the journal Brain (Whelan et al., 2018). This initial
project solidified a framework for future large-scale investigations of
the epilepsies, with several in vitro, in vivo, and postmortem follow-up
investigations currently ongoing, as outlined below.
2.2 | White matter abnormalities across different
epilepsy syndromes in adults
Following the launch of the structural MRI study, efforts within the
consortium shifted toward meta-analysis of DTI data. Our scientific
premise was that epilepsy is a network disorder with widespread
white matter injury to regions that extend far beyond the identified
seizure focus with patterns that may be unique to each syndrome. We
elected to maintain a similar approach to the analysis followed in the
structural MRI study. However, there was consensus that further
dividing the epilepsy syndromes would be informative. As a result,
patients with TLE were divided into those with and without hippo-
campal sclerosis (HS) given prior evidence that these patient groups
may have different epileptogenic networks and harbor different pat-
terns of white matter loss (Mueller et al., 2009; Zaveri, Duckrow, De
Lanerolle, & Spencer, 2001). Our final sample consisted of 1,069
healthy controls and 1,466 patients with epilepsy, including mesial
TLE, nonlesional TLE (TLE-NL), GGE, and nonlesional extratemporal
epilepsy (ExE), making this the largest epilepsy DTI imaging study to
date. As a secondary analysis, we compared the effect size estimates
obtained in our aggregate group of epilepsy patients to those
obtained by other ENIGMA working groups, including MDD, SCZ,
bipolar disorder (BPD), and 22q11 syndrome.
We initially attempted the meta-analytic approach previously
used in ENIGMA-MDD (van Velzen et al., 2019) and ENIGMA-SCZ
(Kelly et al., 2018). However, this strategy was not ideal for our
patient data set, which included many different syndromes across
many sites. Although the contrasts of “all patients in aggregate” versus
controls produced robust and meaningful results, the syndrome-
specific results did not seem biologically plausible, likely due to the
small number of participants per syndrome at many sites. Therefore,
we instead pooled all the data together in a mega-analysis—an
approach that aggregates individual-participant data across sites.
Compared with meta-analyses, mega-analysis uses a more exact likeli-
hood specification, which avoids the assumptions of within-study nor-
mality and known within-study variances, such as sites with few
subjects, rare diagnoses, and/or unbalanced sample size between con-
trols and patients (Burke, Ensor, & Riley, 2017). This approach also
boosts statistical power and provides greater control of confounders
at the individual subject level (Debray, Moons, Abo-Zaid, Koffijberg, &
Riley, 2013). Mega-analyses are also robust to missing data and do
not require imputation or removal of entire subjects when single data
points are missing. The main reason for missing values in this data set
were the removal of extreme outliers (greater than ±3SD) which was
between 1 and 5 regions of interest per site per diffusion parameter.
Aggregating DTI data across sites also requires careful data har-
monization given the known variability in diffusion parameters across
scanner platforms. Following the approach utilized in two prior mega-
analyses, we applied a novel batch-effect correction tool, ComBat, to
adjust for scanner/site specific variations in diffusivity measures
(Fortin et al., 2017; Villalón-Reina et al., 2019; Zavaliangos-Petropulu
et al., 2019). ComBat uses an empirical Bayes framework to improve
the variance of the parameter estimates, assuming that all regions of
interest share the same common distribution. Inspection of the
corrected data suggested that ComBat successfully harmonized across
the sites/scanner instances while maintaining syndrome-specific fea-
tures that were biologically plausible.
Findings from our harmonized mega-analysis revealed microstruc-
tural abnormalities across major association, commissural, and projec-
tion fibers in patients with epilepsy (Figure 3). In our aggregate
analysis of all patients, lower FA was observed in most white matter
pathways, especially in the genu and body of the corpus callosum
(CC), cingulum (CING) and external capsule (EC). Syndrome-specific
FA/MD differences were most pronounced in patients with MTLE,
with large effect size differences in the ipsilateral parahippocampal
cingulum and EC, and small to medium effect sizes across most other
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tracts. TLE-NL showed a similar ipsilateral greater than contralateral
pattern, but with smaller effect size differences compared with MTLE.
Patients with GGE and ExE demonstrated the most pronounced effect
size differences in the CC and EC (FA), and anterior corona radiata
bilaterally (FA/MD). Earlier age of seizure onset and longer disease
duration were associated with altered white matter microstructure in
patients with right and left MTLE. As a whole group, patients showed
white matter perturbation in anterior, midline fibers, while the sever-
ity was different across the epilepsy syndromes. We observed a simi-
lar pattern of results in epilepsy patients to those observed in MDD,
SCZ, and BPD. We believe that these data can further inform our
understanding of epilepsy as a white matter network disorder with
both nonspecific (i.e., shared across brain disorders) and syndrome-
specific microstructural alterations. A next step for our consortium will
be to test whether white matter alterations identified in our mega-
analysis can predict postoperative seizure outcome or to discriminate
patients who are drug-responsive from those who are drug-resistant.
These follow-up studies will also explore age and sex effects more
comprehensively. Finally, there is interested in combining the
T1-derived structural data with the DTI-derived diffusion data to
investigate the multimodal interplay of brain structure and connectivity
in epilepsy. The current study is under review, with a preprint available
at https://www.biorxiv.org/content/10.1101/2019.12.19.883405v1.
2.3 | Gene expression and brain maps
As outlined above, the structural MRI analysis revealed widespread
differences in cortical thickness in people with epilepsy compared
with healthy controls. Although many cortical regions appeared to be
vulnerable (i.e., showed significantly thinner cortices) other regions
appeared to be unaffected by (protected from) the disease. In this
F IGURE 3 White matter abnormalities across different epilepsy syndromes in adults. Top: FA and MD across all patients with epilepsy. BCC,
body of corpus callosum, GCC, genu of corpus callosum; SCC, splenium of corpus callosum; ACR, anterior corona radiata; ALIC, anterior limb of
internal capsule; CGC, cingulum (cingulate gyrus); CGH, cingulum (hippocampal); CST, corticospinal tract; EC, external capsule; FX.ST, fornix (stria
terminalis); PCR, posterior corona radiata; PLIC, posterior limb of internal capsule; PTR, posterior thalamic radiation; RLIC, rentrolenticular part of
internal capsule; SCR, superior corona radiata; SFO, superior fronto-occipital fasciculus; SLF, superior longitudinal fasciculus; SS, sagittal stratum;
TAP, tapetum; UNC, uncinate. Bottom: Radar plots of FA (left) and MD (right) across epilepsy syndromes
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follow-up project, we integrated these imaging results with the
detailed brain-wide gene expression atlas generated by the Allen Insti-
tute of Brain Science (Hawrylycz et al., 2012), to investigate whether
there was a molecular biological signature that explains the regional
vulnerability. Briefly, the gene expression atlas combines data from six
donors and provides the expression level for each of more than
F IGURE 4 Gene expression and brain maps. The study strategy leading to implication of microglia in cortical thinning. eQTL, expression
quantitative trait loci; ILAE, International League against Epilepsy; EpiPGX, Epilepsy Pharmacogenomics: delivering biomarkers for clinical use
project, www.epipgx.eu; LD, linkage disequilibrium; LPS, lipopolysaccharide
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21,000 genes at 3,702 locations in the cortex, subcortical regions, and
the cerebellum.
Our analysis found that over 2,500 genes exhibited higher
expression in vulnerable regions compared with protected regions
(Altmann et al., 2018). Detailed analysis of these overexpressed genes
showed enrichment for genes related to microglia and inflammation,
which suggested that vulnerable regions might exhibit a higher den-
sity in microglia. By further studying postmortem brain tissue from
individuals with nonlesional epilepsy, lesional epilepsy, and non-
epilepsy controls, we found higher microglia density across all tested
regions in samples from people with epilepsy compared with controls.
Thus, these results were consistent with the view that there was an
over-representation in brain tissue from people with chronic epilepsy
and that such microglial responses may occur in a regionally specific
manner. Finally, we turned to a mouse model of acquired epilepsy (Iori
et al., 2017) to establish a causal link between microglia activity and
cortical thinning. The experiments revealed cortical thinning in the
entorhinal cortex in epileptic mice compared with control mice, which
was partially due to reduced neuronal cell density and average neuro-
nal size. Importantly, appropriately timed microglial depletion (through
treatment with PLX3397) could prevent or substantially reduce the
amount of observed cortical thinning. The rescue was mainly acting
on neuronal cell density (neuronal size changes were not rescued).
Thus, taken together these findings incriminate potentially modifiable
microglial activation states in cortical thinning in the common human
epilepsies, and illustrate the value of the MRI data set available in
ENIGMA-Epilepsy (Figure 4): no other tool (PET, histopathology)
would have generated such a large-scale and well-powered initial data
set to drive these follow-on analyses. This study is ongoing.
2.4 | Secondary proposals
In addition to the main projects listed above, group members pro-
posed their own projects making the best use of the gathered data.
The current projects are listed below. Further projects are anticipated.
2.4.1 | Structural correlates of mild mesial
temporal lobe epilepsy with and without hippocampal
sclerosis
TLE is the most common form of focal epilepsy in adulthood. When
seizures start in the internal portion of the temporal lobe, the syn-
drome is called mesial TLE (MTLE), which accounts for 80% of TLE
cases. More than 30% of patients with MTLE do not respond to anti-
epileptic medications, whereas a mild form of MTLE (mMTLE) has
been recently described, which is characterized by seizure onset in
adulthood, unremarkable past medical history, viscero-sensory auras,
and long-term seizure freedom (>24 months) with or without anti-
epileptic medication (Labate et al., 2011). Approximately one third of
patients with mMTLE have MRI evidence of hippocampal sclerosis
(HS), which was previously considered a hallmark of refractoriness.
Mild MTLE represents an important opportunity to better delineate
the biological substrates underlying the epileptic syndrome itself, and
the ENIGMA-Epilepsy project has provided a unique chance to carry
on this investigation over a very large cohort of subjects. Adult-onset
mMTLE often provides few clues to suspect delayed appearance of
refractoriness. Very recently, a longitudinal study has shown the long-
term outcome of patients with mMTLE over a mean follow-up of
12 years (Labate et al., 2016). Over this period, 25% of the patients,
who all had mMTLE at time of enrolment, eventually developed
refractoriness. Survival analysis showed that mMTLE patients carrying
radiological evidence of HS since recruitment have a three times
higher likelihood of becoming refractory later on in life than those
without HS.
In the light of these findings, and with the support of the
ENIGMA-Epilepsy Working Group, we are using locally-processed
T1-weighted MRI data from multiple centers to investigate differ-
ences in mMTLE patients divided on the basis of the presence/
absence of HS, since this has been found to be the major risk factor
for development of refractoriness. This provides an unprecedented
chance to study this relatively benign syndrome on a larger scale, to
test the hypothesis that people with mMTLE with HS may present dif-
ferent patterns of subcortical atrophy and cortical thinning compared
with patients without HS and to healthy controls. While the first stage
of the project has taken into account only structural data, in the future
we aim to integrate data from the DTI study of ENIGMA-Epilepsy, to
investigate potential white matter correlates specific to mMTLE
with HS.
2.4.2 | Structural covariance networks and
network-based atrophy modeling
The adoption of mathematical techniques to study complex systems
in neuroimaging has led to a shift in understanding healthy and dis-
eased brains away from a focus on individual regions, and toward
approaches highlighting the importance of large-scale brain networks
(Bassett & Sporns, 2017; Bullmore & Sporns, 2009). Indeed, network
neuroscience methods have become increasingly important to study
brain development as well as aging, to capture typical inter-individual
variations in structural and functional measures, and to understand
the impact of disorders on whole-brain structure and function
(Fornito, Zalesky, & Breakspear, 2015; Stam, 2014).
Our knowledge of epileptic disorders has undergone a similar
paradigm shift, with focal epilepsies being increasingly conceptual-
ized as conditions affecting large-scale cortical and subcortical net-
works (Bernhardt, Bonilha, & Gross, 2015; Engel Jr et al., 2013;
Gleichgerrcht, Kocher, & Bonilha, 2015; Richardson, 2012; Tavakol
et al., 2019). Using measures of brain morphology, such as cortical
thickness or subcortical volumetry, a series of studies has investi-
gated inter-regional structural networks by analyzing correlational
patterns in morphological measures across patient populations suf-
fering from both focal and generalized seizures. These structural
covariance analyses tap into the coordinated morphology of
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different brain areas, with high covariance being often observed in
regions also undergoing similar maturational trajectories during
development and in regions participating in similar functional net-
works (Alexander-Bloch, Raznahan, Bullmore, & Giedd, 2013). In epi-
lepsy, initial evidence on the capacity of covariance analyses to tap
into network-level disease effects has come from previous work
focusing on the covariance of specific regions, seeding from nodes in
the mesial temporal lobe in drug-resistant TLE (Bernhardt
et al., 2008; Mueller et al., 2009) or from the thalamus in patients
with GGE (Buckner et al., 2009). These studies have often demon-
strated perturbations in the covariance patterns of such disorder-
associated regions. Other studies have assessed inter-regional
covariance more systematically, aggregating covariance patterns
between multiple seeds to derive large-scale network representa-
tions (Bernhardt, Chen, He, Evans, & Bernasconi, 2011; Yasuda
et al., 2015). These networks of coupled cortical and subcortical
morphology have frequently been analyzed using graph theoretical
measures to shed light onto topological properties and organiza-
tional principles (Rubinov & Sporns, 2010). In patients with drug-
resistant epilepsy, several covariance analyses have been published
to date, complementing work based on resting-state fMRI (rsMRI)
and DTI tractography (Bernhardt et al., 2019; Bonilha et al., 2015;
Liu, Chen, Beaulieu, & Gross, 2014; van Diessen et al., 2014).
Although such studies report heterogeneous findings, the majority
of findings indicate that “focal” epilepsies are paradoxically associ-
ated with marked reconfigurations of structural network topology,
often involving increases in path length (indicating reduced global
efficiency) and clustering (indicating tighter cohesion of local com-
munities) TLE patients relative to controls.
In addition to covariance analyses, the cortical morphological fea-
ture data and specifically disorder-related atrophy maps produced
during the first phase of the ENIGMA-Epilepsy can also be related to
network-level structural, functional, and diffusion measures seen in
healthy populations. In several neurodegenerative and neuropsychiat-
ric conditions, such paradigms have proven useful to link cross-
sectional patterns of structural compromise with normative network
organization, for example in the context of building models of regional
susceptibility. Assessing different neurodegenerative and psychiatric
disorders has for example indicated that network hubs (i.e., regions
with many connections) are generally susceptible to marked atrophy
in many disorders (Buckner et al., 2009; Crossley et al., 2014), poten-
tially due to their high metabolic activity, their high plasticity, and par-
ticipation across multiple networks. Complementing such “nodal
stress” models, a series of studies has also assessed spatial similarity
between disorder-specific atrophy maps and different connectivity
measures centered on specific seeds, in order to identify “epicenters”
of network-level structural compromise (Zeighami et al., 2015; Zhou,
Gennatas, Kramer, Miller, & Seeley, 2012).
The ENIGMA-Epilepsy data set provides the added opportunity
of studying structural covariance networks across syndromes
(e.g., TLE, GGE, other epilepsies) in the largest cohort of epilepsy
patients available to date. In addition, structural atrophy and covari-
ance maps can be combined with normative connectivity data in order
to yield network-level support for pathological epicenters in the com-
mon epilepsies.
2.4.3 | Disease progression modeling in epilepsy
The first publication by the ENIGMA-Epilepsy working group rev-
ealed widespread differences in cortical thickness as well as vol-
umes of subcortical structures in people with epilepsy compared
with controls (Whelan et al., 2018). It remains unclear whether
these differences represent developmental differences (i.e., reduced
cortical thickness and volumetric differences are more prevalent in
people who are more likely to develop epilepsy) or are the result of
atrophy as the disease progresses. The data presented by Whelan
et al. (2018) showed negative correlations between cortical thick-
ness and subcortical volumes and disease duration, suggesting pro-
gressive atrophy in the common epilepsies. However, the gold
standard to establish causality between disease and atrophy are
longitudinal studies that quantify the loss of gray matter between
two or more MRI scans. Recently, such a study comprising 190 peo-
ple with epilepsy and 141 controls showed widespread cortical
thinning exceeding normal aging effects (Galovic et al., 2019).
Taken together there is evidence supporting the progressive nature
of gray matter loss.
A complementary approach to the longitudinal study design are
disease progression models, which, broadly speaking, can leverage
cross-sectional data to infer the underlying longitudinal model of
change (Oxtoby, Alexander,,, & EuroPOND consortium, 2017). One
such approach is the Event Based Model (EBM), which was intro-
duced in the domain of familial Alzheimer's disease and Huntington's
disease (Fonteijn et al., 2012) and has by now found wide application
in many brain disorders. Briefly, the idea behind the EBM is that if one
biomarker (A) typically reaches an abnormal level before a second bio-
marker (B) reaches an abnormal level, then in a data set we expect to
see many people who have abnormal levels of biomarkers A alone, or
A and B together. However, we would expect to see few people with
abnormal levels of biomarker B but normal levels of biomarker A.
Given a data set, the EBM uses this reasoning across all subjects and
biomarkers to reconstruct the most likely order in which biomarkers
reach abnormal levels over the course of the disease. In the case of
ENIGMA-Epilepsy, volumes of subcortical structures and regional cor-
tical thickness are treated as separate biomarkers. During the training
phase, the EBM converts each subjects' biomarkers into probabilities
of these biomarkers being abnormal; next, it evaluates possible bio-
marker orderings and seeks to find the ordering that maximizes the
likelihood of the observed biomarker pattern in the entire data set.
Stability of this ordering is assessed using cross validation. After the
EBM has been trained, it provides the most likely ordering of bio-
markers, which can improve understanding of the disease process, for
example by uncovering that hippocampal atrophy precedes atrophy in
the thalamus. More importantly however, a new subject can be objec-
tively staged (i.e., the most likely stage is computed) using the trained
EBM. For instance, the EBM is trained on 10 biomarkers, then,
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subjects can be assigned a stage from zero to 10, meaning that none
or all biomarkers have reached abnormal levels, respectively. Practi-
cally, a stage of k means that the first k biomarkers (in the order esti-
mated by the EBM) have reached abnormal level in the given subject.
The inferred stage can then be linked in subsequent analyses to clini-
cal markers of disease severity or prognosis.
Within this secondary project, we are applying the EBM to the
collected structural MRI data with the aim to infer the order in which
brain regions show abnormal values of gray matter in TLE, GGE, and
other epilepsies. Of particular interest is the comparison between left
and right TLE and whether the biomarker order in left TLE is the same
as in right TLE, just with swapped laterality. Moreover, the project will
investigate whether the EBM staging corresponds to duration of ill-
ness or markers of disease severity, and thus may be of clinical value.
2.4.4 | Resting state functional connectivity in
people with TLE
TLE can be considered a disorder involving a discrete set of limbic and
paralimbic brain regions involved in the generation and propagation of
seizures. However, human and animal models have shown that
numerous cortical and subcortical brain regions are involved in the
condition. These findings support the view that seizure activity in
focal epilepsy originates within intra-hemispheric networks, which is
particularly relevant in understanding impairments in higher order
brain functions that commonly occur with the condition.
RsfMRI allows the identification of atypical functional connectiv-
ity within and between large-scale brain networks and provides a
unique opportunity to study dysfunctional brain architecture. Prelimi-
nary evidence from resting state studies suggests that the condition
chronically alters activity in brain networks controlling basic functions
such as cognition, attention, and emotion (Seeley et al., 2007; Buck-
ner, Andrews-Hanna, & Schacter, 2008; Harrison et al., 2008; Sheline,
Price, Yan, & Mintun, 2010; van den Heuvel & Hulshoff Pol, 2010;
Clemens et al., 2011; Cataldi, Avoli, & de Villers-Sidani, 2013): these
findings need to be validated in larger samples.
Through the ENIGMA-Epilepsy working group, we have launched
a multicenter study to identify atypical functional connectivity in
resting-state networks in people with TLE. This study will enable the
validation of preliminary findings of network abnormalities reported in
people with epilepsy, advance our understanding of disordered func-
tional anatomy in TLE and provide insights into clinical manifestations
of TLE that are currently unexplained.
2.4.5 | Using imaging and genetic data sets to
explore the mechanisms underlying additional
phenotypes in the epilepsies: Drug resistance and
sudden unexpected death in epilepsy
In clinical epilepsy practice, there are many important phenotypic fea-
tures that are unexplained. Amongst these are the phenomenon of
drug resistance, with seizures that continue to occur despite treat-
ment with appropriate antiseizure drugs: drug resistance occurs in
about 30% of patients, and is associated with higher rates of com-
orbidities and premature mortality (Löscher, Potschka, Sisodiya, &
Vezzani, In press). Sudden unexpected death in epilepsy (SUDEP) is a
tragic outcome which affects an incidence of at least 1 per 1,000
patient years, with higher rates in people with uncontrolled general-
ized tonic–clonic seizures (Whitney & Donner, 2019). Neither impor-
tant aspect of the epilepsies is currently preventable, nor fully
understood. In SUDEP, brain structural and functional imaging abnor-
malities have been reported (Allen et al., 2017; Allen et al., 2019;
Allen, Harper, Lhatoo, Lemieux, & Diehl, 2019; Wandschneider
et al., 2015), but these are from comparatively small studies.
ENIGMA-Epilepsy offers the chance to study these aspects of epi-
lepsy in larger numbers of patients, and both drug resistance and
SUDEP are active areas of study in ENIGMA-Epilepsy, with the added
value that genetic data can also be merged with information from
processed MRI data.
2.4.6 | Deep learning
Deep learning, a type of machine learning, can be broadly summarized
as artificial intelligence (AI), which collectively offers the benefits of
identifying patterns in complex data and out-of-sample prediction. It
can provide some additional insights, typically if very large data sets
are employed.
In the context of neuroimaging, patterns in complex data can be
difficult for the human eye to fully grasp, particularly when multiple
dimensions are present. For example, it is relatively straightforward to
appreciate that the hippocampus may exhibit atrophy on T1 weighted
images, hypometabolism on interictal nuclear medicine studies and
high-probability of being a generator of interictal discharges on high-
density EEG source reconstruction. However, it becomes more diffi-
cult to fully appreciate the complexity of multiple dimensions when
broader networks are involved and do not fully overlap, or when there
are more subtle abnormalities. In this context, AI offers the benefits of
“filtering” this information and providing a summary of the concordant
versus nonconcordant information from multiple modalities. This is
particularly relevant when imaging modalities such as functional or
structural connectivity are taken into account, since these can be
somewhat difficult to visualize. AI can provide important decision sup-
port tools for the identification of clinical phenotypes.
Machine learning applied to epilepsy is still in its nascent stages,
but there have been promising results from pilot studies suggesting
that it can be sensitive to abnormalities related to the disease. For
example, previous work has demonstrated high accuracy in discrimi-
nating the brains of people with TLE from those of healthy controls
using support vector machine (SVM) based on microstructural abnor-
malities in the medial inferior aspect of the temporal lobes (Del Gaizo
et al., 2017). Using multimodal imaging, Bennet et al. demonstrated
that seizure laterality could be predicted with high accuracy in MRI-
positive and MRI-negative cases of TLE based on hippocampal or
12 SISODIYA ET AL.
temporal lobe information, respectively (Bennett et al., 2019). Impor-
tantly, Kamiya demonstrated that DTI structural brain connectomes
(which are invisible to the human eye) could be accurately used for
lateralization of TLE (Kamiya et al., 2016). These studies underscore a
few important points:
1 Conventional machine learning could be helpful for detecting invisi-
ble patterns in TLE that could help to lateralize seizure onset and
possibly predict clinical outcomes (e.g., neuropsychological func-
tion) (Bennett et al., 2019; Del Gaizo et al., 2017; Frank
et al., 2018; Kamiya et al., 2016; Munsell et al., 2019).
2 The findings so far have been mostly restricted to TLE. Arguably,
phenotyping other forms of epilepsy may be of greater importance
since these are the most challenging cases, for which computer-
aided diagnosis may be most needed.
3 While conventional machine learning is a powerful form of AI, deep
learning offers a wider range of applications and potentially better
accuracy. Given their high parametric complexity, these algorithms
may perform particularly well when leveraging big data sets.
ENIGMA-Epilepsy provides a large representative multimodal
imaging data set across multiple centers, being thus optimal for the
application of deep learning in epilepsy. The limitations related to
sample size and representativeness of data are minimized by the col-
laborative environment and by the breadth of data. We recently
obtained NIH support for a pilot project (NINDS R21) to evaluate
whether deep learning is better in classifying TLE in comparison with
conventional machine learning, as well as whether deep learning can
successfully predict seizure outcomes following epilepsy surgery.
After this initial step is complete, future directions by ENIGMA-
Epilepsy will include: (a) leveraging complex connectome-based neural
network patterns, arguably reaching at the core of pathophysiology of
epilepsy, and leveraging deep learning ability to segment features into
subnetworks; (b) assessing convolutional neural networks with
unprocessed T1 weighted data or K-space data; and (c) the expansion
of these approaches to extratemporal epilepsy Figures 1–4.
2.4.7 | Structural changes at onset of illness
Diagnosis and management of patients who experience an event with
transient neurological deficit or loss of consciousness for the first time
is a challenging task, especially if no structural epileptogenic lesion
can be detected. Routine diagnostic methods to identify patients with
new-onset epilepsy are of limited sensitivity. A prospective multicen-
ter study based in Switzerland, “Predict and Monitor Epilepsy after a
First Seizure: The Swiss First Study” aims to determine EEG and MRI-
based biomarkers that identify network abnormalities characterizing
people with epilepsy. Neuroimaging research has mainly focused on
patients with a long history of epilepsy (Crocker, Pohlmann-Eden, &
Schmidt, 2017). With a mean disease duration of 17.4 years
(± 12.0 years), the ENIGMA-Epilepsy cohort comprises predominantly
people with long-standing epilepsy (Whelan et al., 2018). It remains
undetermined if and which structural abnormalities constitute pre-
clinical cortical reorganization caused by a predisposition to epilepsy
or whether such abnormalities develop as a consequence of the ongo-
ing illness (see also Section 2.4.3).
To address this question, a sub-analysis of the ENIGMA-Epilepsy
data set in patients with short duration of the disease is being exe-
cuted within this secondary project. People will be stratified into
cohorts of recent-onset epilepsy (illness duration ≤ 2 years), short ill-
ness duration (duration ≤ 5 years) and chronic epilepsy (duration
>5 years). Despite the strict restrictions in the first two subgroups,
the group sizes reachable via the ENIGMA-Epilepsy collaboration are
expected to be much larger than possible in single-center studies. We
will explore differences between these three cohorts and matched
healthy control groups. This sub-analysis of the retrospectively-
collected ENIGMA-Epilepsy structural MRI data set might generate
new hypotheses for people with new-onset epilepsy paralleling the
prospective Swiss First study.
3 | FUTURE PLANS
Membership of ENIGMA-Epilepsy continues to grow: indeed, we
invite researchers prompted to join our consortium as a result of this
article to make contact as detailed below. Methods development
within ENIGMA and across its constituent members provides tools for
additional analyses of existing and new data. ENIGMA-Epilepsy also
intends to move to a centralized approach that involves sharing raw
data, subject to the necessary governance structures, permitting for-
mal mega-analyses, as have a number of other groups in ENIGMA.
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